## SENTARA HEALTH PLANS

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-800-750-9692</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process may be delayed.</u>

Drug Requested: Cabenuva<sup>™</sup> (cabotegravir/rilpivirine) LAP (Pharmacy)

ME	MBER & PRESCRIBER INFORMATION	: Authorization may be delayed if incomplete.		
Memb	er Name:			
	er Sentara #:			
Prescr	iber Name:			
Prescr	iber Signature:	Date:		
Office	Contact Name:			
	Number:			
DEA (	OR NPI #:			
DRU	JG INFORMATION: Authorization may be del	ayed if incomplete.		
Drug 1	Name/Form/Strength:			
Dosin	g Schedule:	Length of Therapy:		
Diagn	osis:	ICD Code, if applicable:		
Weigh	nt: 1	Date:		
suppo	NICAL CRITERIA: Check below all that apply ort each line checked, all documentation, including ladded or request may be denied.			
	Member is 12 years of age or older			
	Member must have a confirmed diagnosis of human	immunodeficiency virus type -1 (HIV-1)		
	Medication is being prescribed by, or in consultation HIV treatment	n with, an infectious disease specialist or specialist in		
	Member has been stabilized <u>AND</u> virologically supposed defined as HIV RNA copies <50 copies/mL (must stabilized from the past 3 months and laboratory of from the past 30 days)	ubmit chart notes/progress notes displaying		
	Member has <u>NOT</u> experienced any treatment failure either cabotegravir or rilpivirine	e and not suspected/known to have resistance to		

(Continued on next page)

PA	Cabenuva	(Pharn	nacy) (C	ORE)
	(Continue	d from	previous	page)

3.5 30 .0			~		-	_		_
Medication	haina	nrovided k	<b>177</b>	nacialts	, Pharmacy	v _ Prc	nrium	Ųν
Miculcation	DUILE	pi o viucu k	$\mathbf{v}$	pecially	i naimac	y — 1 1 (	, pri iuiii	1//

<sup>\*\*</sup>Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. \*\*

<sup>\*</sup>Previous therapies will be verified through pharmacy paid claims or submitted chart notes. \*